PiaSky® (crovalimab) Dosing & Administration

Treatment on your patients’ terms: PiaSky® can be taken at home once every 4 weeks1-3

The initial PiaSky® loading dose is one IV infusion, administered by a healthcare provider. The next 4 loading doses are subcutaneous injections, given once per week. Maintenance doses are then administered once every 4 weeks subcutaneously, with no further IV infusions required. Patients can self-inject PiaSky® after the initial loading dose and after receiving training from their healthcare provider.

PiaSky® offers your patients a different way to administer their treatment, by allowing subcutaneous self-injections outside of a healthcare setting.

Product photo

Administer PiaSky® doses based on body weight3

PiaSky® is prepared and administered in a series of simple steps5

Preparing the injection

Administering PiaSky®

*Patients starting PiaSky® will receive an initial weight-based loading dose through IV infusion. Four subsequent loading doses are then given weekly by subcutaneous injection. Weight-based maintenance dosing is then administered once every 4 weeks subcutaneously. Patients may self-inject after receiving training from their healthcare provider.
IV = intravenous; Q4W = 4-weekly; SC = subcutaneous.
References
  1. Röth A, et al. Am J Hematol. 2024;99:1768–1777.
  2. Scheinberg P, et al. Am J Hematol. 2024;99:1757–1767.
  3. PiaSky® (crovalimab) 170mg/mL solution for injection Summary of Product Characteristics. F. Hoffmann-La Roche; 2024.
  4. Rӧth A, et al. Blood. 2020;135:912–920.
  5. PiaSky® (crovalimab) 170mg/mL solution for injection Package Leaflet. F. Hoffmann-La Roche; 2024.
  6. Overton P, et al. Patient Prefer Adherence 2021:15:811–834.